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OBJECTIVE — Increased urinary albumin excretion rates have been linked to nephropathy
and macrovascular disease. We here describe the baseline prevalence and effect of Diabetes
Prevention Program (DPP) interventions on the development and reversal of elevated albumin
excretion.
RESEARCH DESIGN AND METHODS — Urine albumin-to-creatinine ratios (ACRs)
were calculated from untimed urine collections. Analyses compared participants by treatment
group, diabetes and hypertension status, and use of ACE inhibitors or angiotensin II receptor
blockers (ARBs).
RESULTS — Elevated ACR levels (30 mg/g creatinine) were present at baseline in 198
(6.2%) of 3,188 participants: placebo 5.3%, metformin 6.5%, and intensive lifestyle (ILS) 6.8%.
Ofthe2,802withACRmeasurementsatbaselineandattheendofthestudy,thepercentagewith
elevated levels declined (incident and regression) from 6.2 to 6.1%, with no signiﬁcant differ-
ences between the groups even with adjustment for ACE inhibitor and ARB use. The odds of
developing an elevated ACR were 59% higher for a participant who developed diabetes com-
pared with one who did not.
CONCLUSIONS — AtentryintotheDPP,anelevatedACRwaspresentin6.2%.Despitethe
marked decrease in progression to diabetes and the improvement in insulin resistance and other
cardiovascularriskmarkersintheILSandmetformingroups,therewasnoimprovementinACR,
on average, in those two groups. However, the frequency of an elevated ACR was higher in
participants who developed diabetes. An increased ACR may have multiple causes, thus obscur-
ing the improvements that might have been expected with the reduction in insulin resistance
seen in the DPP.
Diabetes Care 32:720–725, 2009
I
ncreased urinary albumin excretion
rates (AERs) have been linked to the
development of diabetic nephropathy
and macrovascular disease in patients
with type 1 and type 2 diabetes (1,2). The
development of increased AER is associ-
atednotonlywithhyperglycemiabutalso
with blood pressure elevations (3–6). Be-
causeofdifﬁcultiesinpreciselytimingthe
onset of type 2 diabetes, the duration and
degree of glucose intolerance necessary
for the development of elevations of AER
have been addressed in large, cross-
sectional, and longitudinal studies. In
cross-sectional studies of Pima Indians,
microalbuminuria was found in 8% of
thosewithnormalglucosetolerance,15%
of those with impaired glucose tolerance
(IGT), and 47% of those with type 2 dia-
betes (7). These studies have also shown
that microalbuminuria was correlated
with insulin resistance (8), rising glucose
levels(9,10),andthepresenceofthemet-
abolic syndrome (11).
The Diabetes Prevention Program
(DPP) was a randomized, prospective,
clinical trial that tested strategies to pre-
vent or delay the development of type 2
diabetes in overweight or obese partici-
pants aged 25 years with elevated fast-
ing glucose and IGT (12,13). We have
previouslyreportedthat28%ofthe3,819
participants initially entered into the
study had hypertension, that the mean
urine albumin was 14 mg/g creatinine,
and that the albumin-to-creatinine ratio
(ACR) had a weak (r  0.09) but statisti-
cally signiﬁcant correlation with systolic
blood pressure (SBP) at baseline (14).
Bothlifestylemodiﬁcationandmetformin
treatmentresultedinsigniﬁcantdecreases
inthedevelopmentofdiabetesduringthe
DPP (13). We now analyze the develop-
ment of elevations in ACR as a function of
time and treatment group during the
DPP.
RESEARCH DESIGN AND
METHODS— Full details of the pro-
tocol, recruitment, and outcomes have
been published (5,6). The current report
includes 3,188 of the 3,234 participants
entering the study who had urine ACR
measurements before randomization.
This number does not include partici-
pants from the troglitazone arm, which
was discontinued.
Inclusion and exclusion criteria have
been published previously (12,13). Perti-
nent to the current analysis, the following
exclusions should be noted: serum creat-
inine1.4mg/dl(124mol/l)formenor
1.3 mg/dl (115 mol/l) for women;
urine protein 2 on one occasion (dip-
stick) in the absence of infection or vagi-
nal contamination; and in individuals
who were or would become 80 years of
age during the study, a direct measure of
creatinine clearance 75 ml/min, based
on a 24-h urine collection.
Standardized interviewer-adminis-
tered questionnaires were used to obtain
self-reported data on personal medical
history, medications, diet, and other fac-
tors. Overall, adiposity was assessed by
BMI. All anthropometric measures re-
ﬂected the average of two measurements.
Bloodpressurewasmeasuredwithastan-
dardmercurymanometerwiththepartic-
ipant seated in a chair for 5 minutes
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by 30 s. The mean of the two readings
wereusedintheanalyses.Hypertensionis
deﬁned as meeting any of three criteria:
SBP 140 mmHg, diastolic blood pres-
sure (DBP) 90 mmHg, or taking medi-
cations that lower blood pressure.
Further details have been published else-
where (5,6,12,13).
Laboratory methods
All of the analytical measurements were
performed at the Central Biochemistry
Laboratory (Northwest Lipid Research
Laboratories, University of Washington,
Seattle, WA) as described previously
(12,13).Pertinenttothecurrentanalyses,
creatinine concentrations in the serum
andurineweremeasuredbyavariationof
the Jaffe method and urine albumin con-
centration was measured by a ﬂuoroim-
munoassay. Albuminuria was assessed
using a spot urine test of albumin and
creatinine. The ACR was used to deﬁne
categories of albuminuria: normal (30
mg/g creatinine), microalbuminuria (30-
300 mg/g creatinine), and macroalbu-
minuria (300 mg/g creatinine). In this
report, the term “elevated ACR” indicates
the combined categories of microalbu-
minuria and macroalbuminuria.
Statistical analyses
For this analysis, participants were fol-
lowed for an average of 3.4 years with the
end of study assessment ranging from 2.4
to 5.4 years, a period 4 months longer
than that reported previously (13) to
maximizetheavailabledatathatwerecol-
lected during the masked phase of the
DPP. Nominal (unadjusted) P values and
conﬁdenceintervalsarereported.Logistic
regression was used to compare the prev-
alence of elevated ACR at baseline and
end of study. Wilcoxon’s signed-rank test
was used to assess whether the paired ACR
levelschangedbetweenbaselineandthe
endofstudywithingroups,whereasthe
Kruskal-Wallis test was used to compare
the ACR levels at the end of the study
among the three treatment groups.
RESULTS
Baseline assessments (n  3,188)
The baseline prevalence of elevated albu-
minuria by baseline characteristics and
treatment group are displayed in Fig. 1.
Elevated ACR levels were present in 198
participants (6.2%), with similar percent-
ages in the three groups: placebo 5.3%,
metformin 6.5%, and intensive lifestyle
(ILS) 6.8%. Only 14 participants in the
entire study had an ACR 300 mg/g cre-
atinine at baseline. ACE inhibitors or an-
giotensin II receptor blockers (ARBs)
were used at baseline in 8.2, 9.9, and
8.6% of the participants in the placebo,
metformin, and ILS groups, respectively.
Atbaselinetherewerenotreatmentgroup
differences, including systolic and dia-
stolic blood pressure, the presence of hy-
pertension, mean urine ACR, or serum
creatinine.
When the baseline ACR measure-
ments were broken down by quartiles
(3.7, 3.7–5.5, 5.5–9.7, and 9.7
mg/g), those with higher ACR levels had
higher BMIs, greater waist circumfer-
ences, higher fasting insulin level, higher
SBP and DBP levels, and greater frequen-
cies of hypertension (Table 1).
Paired baseline and end of study
assessments (n  2,802)
Of the participants with baseline evalua-
tions, 2,802 had measurements per-
formed at the end of the study. In these
2,802 participants the total number with
elevatedACRlevelsdidnotchangesignif-
icantly, going from 174 (6.2%) to 171
(6.1%) participants, after a mean of 3.4
years in the study. These numbers com-
prise both a regression to normal from
prior elevated levels plus incident cases
(Table 2). The net change in individuals
moving from normal to elevated ACR
(numbers worsening minus numbers re-
gressing)were9(placebo),0(metformin)
and 12 (ILS). Overall, there were more
improvements in the ILS group and more
individuals who worsened in the placebo
group, although this difference was not
statistically signiﬁcant (P  0.07) (Table
2). Despite the signiﬁcant decrease in the
incidence of diabetes among the ILS and
metformin groups compared with the
placebo group, there were only minimal
andnotstatisticallysigniﬁcantdifferences
in the frequency of elevated ACR levels
between the groups (placebo 6.3%, met-
formin 6.7%, and ILS 5.4%) at the end of
the study. The median ACR levels in all
three groups did not change signiﬁcantly
and the changes did not differ signiﬁ-
cantly among the treatment groups: pla-
cebo 0.10 mg/g creatinine, metformin
0.12 mg/g creatinine, and ILS 0.06 mg/g
creatinine. Although at the end of the
study, the frequency of SBP 140 mmHg
was lower in the ILS group (10.1%) than
in the other two groups (placebo 12.2%
and metformin 12.6%), this difference
was not signiﬁcantly different. The differ-
ences in frequencies of DBP 90 mmHg
at the end of the study approached signif-
icance (P  0.056) among the three
groups: ILS 5.7%, metformin 8.5%, and
placebo 6.7%.
The frequency of ACE inhibitor or
ARB use increased in all three groups,
from 8.3 to 23% in the placebo group,
from 9.6 to 23.3% in the metformin
group, and from 8.7 to 17.9% in the ILS
group. The increase in the ILS group was
signiﬁcantly less than that in the other
twogroups(P0.023),possiblybecause
of the slightly lower frequency of hyper-
tension at the end of the study in this
group.Weperformeddetailedanalysesto
determine incident new cases of elevated
ACR levels versus regression to normal,
withandwithoutuseofACEinhibitorsor
ARBs, because the use of these drugs at
baseline might have prevented the detec-
tion of a possible elevated level and the
institution of therapy with these drugs
mighteithercauseregressiontonormalof
preexisting elevated levels or prevent the
development of abnormal levels. For ex-
ample, of the 931 ILS participants who
had a baseline and end-of-study assess-
ment for ACR, 62 (6.7%) had elevated
levels at baseline. However, there were an
additional 71 (7.6%) participants who
were taking ACE inhibitors or ARBs.
Thus, the prevalence of elevated ACR at
baseline, when unmasked by concurrent
useofACEinhibitorsorARBs,couldhave
been between 6.7 and 14.3%. Among the
869 ILS participants who did not have
elevatedACRlevelsatbaseline,28(3.2%)
had elevated ACR levels at the end of
study examination and an additional 70
(8.1%) participants initiated treatment
with ACE inhibitors or ARBs after base-
line,sotheincidenceofanincreasedACR
rangedfrom3.0to11.3%.Conversely,40
of the 62 participants (64.5%) with ele-
vatedACRlevelsatbaselinenolongerhad
elevated levels at the end of study; how-
ever, 18 of these 40 were taking ACE in-
hibitors or ARBs so the resolution of an
elevated ACR level ranges from 35.5 to
64.5%. When the overall prevalence
(new incidence cases and reversal of ele-
vatedACRlevels)forthethreegroupswas
analyzed in this way, the estimates of ele-
vated ACR levels at the end of the study
werenotsigniﬁcantlydifferentamongthe
three treatment groups, even adjusted for
ACE inhibitor and ARB use. In addition,
the treatment assignments had no signif-
icant effect on log ACR at the end of the
study whether or not adjustments were
made for the baseline covariates: log-
Diabetes Prevention Program Research Group
DIABETES CARE, VOLUME 32, NUMBER 4, APRIL 2009 721Figure 1—Prevalence of elevated ACR levels at baseline by subgroups. The height of the bars represents the percentage of subjects with an elevated
ACR(30mg/g),frepresentsmicroalbuminuria(ACRbetween30and300),and representsmacroalbuminuria(ACR300).Theprevalence
of albuminuria differed among subgroups for age, race/ethnicity, SBP, DBP, and BMI (P  0.05).
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blood pressures, use of ACE inhibitors/
ARBs, age, sex, and race/ethnicity.
The odds of developing an elevated
ACR level were 59% higher for a partici-
pant who developed diabetes compared
with one who did not, and there was no
difference among the three treatment
groupsinthisregard(Fig.2).Participants
in the placebo group who developed dia-
betes experienced a signiﬁcantly greater
change in ACR compared with those
without diabetes (P  0.036; median
0.02 vs. 0.34 mg/g creatinine) (Fig. 3),
although these changes were so small as
to be of little clinical importance. The
presence of hypertension also increased
the median ACR in diabetic and nondia-
beticparticipantsineachtreatmentgroup
(Fig. 3).
CONCLUSIONS — In participants
entering the DPP, the frequency of an el-
evated ACR level was 5.8%, a proportion
considerably lower than that found in
other comparable populations. In the
Third National Health and Nutrition Ex-
amination Survey (1988–1994), mi-
croalbuminuria was present overall in
7.8% of women and 5.0% of men but in
those with the metabolic syndrome, mi-
croalbuminuriawasfoundin12%ofmen
and 13% of women (11). As mentioned
previously,15%ofPimaIndianswithIGT
havemicroalbuminuria(7).Inotherstud-
iesinsubjectswithIGT,9.9%ofAustralians
(15), 14 (16) and 24% (17) of Japanese,
11.8%ofKoreans(18),and19%ofIndians
had microalbuminuria (19).
The reasons that our participants had
such low rates of elevated ACR levels are
not clear. Blood pressure was particularly
well controlled (mean SBP 123.7  14.7
andmeanDBP78.39.3mmHg).These
blood pressures are substantially lower
than those found in the patients with mi-
croalbuminuria in the Australian Diabe-
tes, Obesity, and Lifestyle (AusDiab)
Study (151  23/78  13 mmHg) (15).
Furthermore, entry exclusion criteria
(creatinine 1.4 mg/dl in men, 1.3
mg/dl in women, creatinine clearance
75 ml/min in subjects aged 80 years,
and 2 proteinuria on dipstick) may
have removed many with or at high risk
for developing elevated ACR. Another is-
sue is the use of ACE inhibitors or ARBs,
which may lower urinary albumin excre-
tion; these drugs were used in 6.7, 8.3,
and 6.1% in the ILS, metformin, and pla-
cebo groups, respectively. As these drugs
were often used for hypertension treat-
ment without knowing baseline albumin-
uriastatus,thefrequencyofelevatedACR
levels could have been as high as 13.0,
14.4, and 11.1% in the ILS, metformin,
and placebo groups, respectively, making
these percentages more in line with the
frequencies found in other studies.
Table 1—Baseline characteristics by ACR quartiles
ACR quartiles
Overall
(mg/g) 3.7 mg/g
3.7 to 5.5
mg/g
5.5 to 9.7
mg/g 9.7 mg/g P
n 3,188 772 818 798 800
Sex (% female) 2,158 (68) 453 (59) 536 (66) 595 (75) 574 (72) 0.001
Age (years) 50.6  10.7 50.0  10.6 50.3  10.4 50.6  10.5 51.6  11.1 0.02
BMI (kg/m
2) 32.5  8.5 31.8  7.2 32.4  7.1 32.3  7.1 33.5  7.2 0.001
Waist circumference (cm) 103  19 102  16 103  16 103  16 106  16 0.001
Fasting glucose (mg/dl) 106  11 106  9 106  9 106  9 107  9 0.12
120-min glucose (mg/dl) 165  24 165  20 164  20 164  20 166  20 0.10
A1C (%) 5.98  0.65 5.94  0.55 5.99  0.54 6.00  0.54 6.00  0.54 0.04
Fasting insulin (U/ml) 23.7  2.1 22.1  1.8 23.6  1.8 23.8  1.8 25.6  1.8 0.001
Systolic blood pressure (mmHg) 124  19 120  16 122  16 124  16 128  16 0.001
Diastolic blood pressure (mmHg) 79  13 77  11 78  10 79  10 81  10 0.001
Data are n (%) for categories and means  SD for continuous variables except for fasting insulin represented as geometric mean. All variables except female sex and
age are adjusted for baseline age, sex, and race/ethnicity.
Table 2—Change in classiﬁcation between normal and elevated ACR from baseline to end of study by treatment group
Baseline End-of-study status Placebo Metformin ILS
Normal ACR 890 (95) 869 (93) 869 (93)
Developed elevated ACR 33 (4) 35 (4) 28 (3)
Remained without elevated ACR 857 (96) 834 (96) 841 (95)
Elevated ACR 50 (5) 62 (7) 62 (7)
Resolved elevated ACR 24 (48.0) 35 (56) 40 (64)
Remained with elevated ACR 26 (52) 27 (44) 22 (35)
Total 940 931 931
Stable status 883 (93.9) 861 (92.5) 863 (92.7)
Worsened albuminuria 33 (3.5) 35 (3.8) 28 (3.0)
Improved albuminuria 24 (2.6) 35 (3.8) 40 (4.3)
Net increase in elevated ACR 9 (1.0) 0 (0.0) 12 (1.3)*
Data are n (%). Elevated ACR is deﬁned as ACR 30 mg/g. *Ptrend  0.07 for test of linear trend between treatment group (placebo to metformin to ILS) and change
in category (worsened to stable to improved).
Diabetes Prevention Program Research Group
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resistance in the DPP, and this has also
been shown in other studies of individu-
als with normal and IGT (8). Therefore, it
would have been expected that the inter-
ventions with ILS and metformin, which
decreased the development of diabetes
and decreased the degree of insulin resis-
tance (20,21), would similarly decrease
albumin excretion and the frequency of
microalbuminuria. Furthermore, met-
formin has previously been shown to de-
crease urinary albumin excretion in
patients with type 2 diabetes (22). How-
ever, this was not the case in the DPP co-
horts. One possible reason is that
although this is the largest study to have
addressed this issue, we still did not have
enough power to detect such changes, as
there were relatively small numbers who
had microalbuminuria at baseline and
there was only a short time to detect inci-
dent cases of microalbuminuria.
The presence of micro- and mac-
roalbuminuria in patients with IGT and
diabetes has been thought to be a marker
of increased cardiovascular risk
(2,23,24).However,despitetheimprove-
ment in insulin resistance and other car-
diovascular risk markers in the ILS and
metformin groups (21,22), there was no
improvement in ACR in those two
groups.
Obesity has been associated with glo-
merular hypertrophy, increased urinary
albumin excretion, and even decreased
glomerularﬁltrationrateintheabsenceof
diabetes in some patients (25). It may be
that the increased ACR found in the DPP
participants has multiple causes, includ-
ing insulin resistance, endothelial dys-
function, early diabetic nephropathy
related to hyperglycemia, hypertensive
nephropathy, and focal sclerosis related
to obesity. We did not adjust for antihy-
pertensive drug use other than ACE in-
hibitors and ARBs, and this may also be a
shortcoming. Thus, the modest changes
in insulin resistance and weight loss that
occurred with active intervention in the
DPP over the relatively short period of time
of 3.4 years may be only one set of factors
thatneedtobecorrectedtoaffectthekidney
disease in this patient population.
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Figure 2—Prevalence of elevated ACR (30 mg/g) at end of study by treatment group and
diabetes(DM)status.Pvalueindicatesthedifferenceinratesbetweenthediabeticandnondiabetic
treatment groups.
Figure 3—Median ACR (milligrams per gram) by diabetes (DM) and hypertension status at end
of study.
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